GS The Goldman Sachs Group, Inc.

The Goldman Sachs Group, Inc. (GS) earns its money as the premier capital-markets franchise — investment banking, equities and FICC trading, plus a growing asset & wealth management book. FY25 (10-K via SEC XBRL): net income $17.18B (up from $14.28B prior year), diluted EPS $51.32, stockholders' equity $125B, ROE ~14%. Trailing TTM diluted EPS is now $54.72 (EODHD), EPS +24% YoY, revenue +14.5% YoY. Note operating cash flow screens negative — a balance-sheet artifact of a broker-dealer, not a cash problem; net income is the right earnings read for this franchise.

Valuation: trailing PE 18.6x, forward 17.2x, P/B 2.74x on a 14.6% ROE — reasonable, not a chase. Beta 1.291.

WHY NOW: GS closed $1,019.61 on 07-01 — the SAME level as its 06-26 dislocation ($1,019.61), ~9% off the $1,125 52-week high, sitting right on the 50d MA ($995) and well above the 200d ($887). It held the pullback for a full week without a franchise crack on the wire — this is the real dislocation I refused to chase on 06-22 when it sat $1,096 at its high, and it has NOT run back up. Tape divorced from franchise. The capital-markets backdrop is constructive: record US share-issuance tape feeds IB and equities, the lines behind four straight double-digit EPS beats (+8% to +19%).

STRUCTURAL ROLE / FUNDING: at β1.291, GS is the high-beta quality leg the campaign has needed since 06-18. Filed as a basket — CME close (broken, -16%, β0.26 dead-money financial, my standing cut) FUNDS GS 2.5% open AND GILD 1.01%→2.0% resize. Checked live: would_clear true, zero breaches; book beta 0.9058→0.9006 (holds the 0.90 floor), cash 1.63%→3.76% (cures the sub-floor breach in the same trade), top-5 87.5%→84.1%. GS's β1.29 carries GILD's pre-committed second β0.33 leg over the floor — the wall that has vetoed every low-vol add since 06-18, honestly cleared. 1-in-1-out (CME→GS), holds count at 11.

STOP / HOW I'M WRONG: Q2 prints 2026-07-14 (est $13.78) — 12 days out, outside the T+1 freeze, and I'm buying 9% off the high WITH runway, not the night-before binary I refused on FDX. The beat streak and issuance tape skew it favorably. Kill if Q2 misses on a franchise line (IB/trading revenue down y/y, not just a provision), if ROE compresses below ~11% structurally, or -15% relative. Print confirms or kills the thesis in two weeks.</thesis_md> <parameter name="catalysts">["Q2 earnings 2026-07-14 (est $13.78)", "record US share-issuance/IPO tape feeding IB + equities", "held the $1,019 dislocation for a week without franchise crack"]